Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

By Peter F. Bross, J. Beitz, Gang Chen, X. H. Chen, E. Duffy, L. Kieffer, Sandip K. Roy, R. Sridhara, Atiqur Rahman, G. Williams and 1 more. Clinical Cancer Research, 2001

884 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/6b130f71029fc2f3f66801fbd4207c5bdad9081b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Kevin J. Hamblett
2. Zhiwen Fu
3. D. Chace
4. Michael M C Sun
5. Kathryn L. Parsons
6. Gail D Lewis Phillips
7. J. Lenox
8. Shijun Li

Citations in the corpus

• Antibody drug conjugate: the “biological missile” for targeted cancer therapy (2022, background): “With a response rate of 26%, it was firstly approved by the FDA for use in patients with relapsed or refractory (r/r) CD33 positive AML in first relapse who were over 60 years and were not suitable for other conventional chemotherapies.(145) Roughly 85–90% of adult and pediatric AML are CD33 positiv”
• Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate (2004, background): “Gemtuzumab ozogamicin, an antibody-drug conjugate that is composed of the potent DNA minor groove binder calicheamicin linked covalently to an anti-CD33 mAb (8), was approved in 2000 by the United States Food and Drug Administration for the treatment of patients with relapsed acute myeloid leukemia ”
• Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (2008, background): “Currently, only one such conjugate, anti-CD33 conjugated to calicheamicin (gemtuzumab ozogamicin or Mylotarg), has been granted marketing approval for the treatment of relapsed acute myeloid leukemia (23).”